​Dear GP2C and Rett University Community – Great news!

Acadia’s DAYBUE (Trofinetide) is now commercially available. See the entire press release HERE!

And to all of our Rett families, please note that Acadia has established comprehensive family support for DAYBUE at Acadia Connecthttps://www.acadiaconnect.com/

Acadia Pharmaceuticals Announces DAYBUE (trofinetide) is Now Available for the Treatment of Rett Syndrome

— Commercial launch of DAYBUE offers Rett syndrome community the first and only approved therapy for Rett syndrome, a rare, neurodevelopmental disorder, which affects 6,000 to 9,000 patients in the U.S.

SAN DIEGO – Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that DAYBUE (trofinetide) is now available for the treatment of Rett syndrome in adult and pediatric patients two years of age and older in the United States. DAYBUE has demonstrated the potential to improve the signs and symptoms of Rett syndrome. DAYBUE was approved by the U.S. Food and Drug Administration (FDA) on March 10, 2023, and is the first and only drug approved by the FDA for the treatment of Rett syndrome. (Read more here!)

Regards, Kevin